68ga p15-041
Small moleculeexperimentalImaging agent
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2016 (NCT02826382)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 68-gallium
Oral
No
Parenteral
No
Topical
No
Also known as
- 68ga p15-041
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06455722 | Early Phase 1 (Phase 1) | Jan 1, 2024 | Fujian Medical University |
| NCT05627778 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2021 | Chinese Academy of Medical Sciences |
| NCT02826382 | Early Phase 1 (Phase 1) | Jul 1, 2016 | Five Eleven Pharma, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Five Eleven Pharma, Inc. | For profit | 1 | 1 | 1 | 2016 |
| Fujian Medical University | Academic/Hospital | 1 | 1 | 1 | 2024 |
3 organizations
Page 1 / 1